Ebos Group Limited Analysis

Overview

Formerly Early Bros Dental & Surgical Supplies Ltd, the company's business was restructured in the 1990s. The major focus now is the marketing of medical consumable products, and growth has been assisted by acquisitions on both sides of the Tasman since 1996. These included Richard Thomson & Co, Health Support Ltd, Maygar Medical, Medic Corporation, Nature's Kiss creams and the Australian Allersearch range of asthma products.

In October 2002 it announced a joint venture of its former Medic Scientific division with Global Science, giving EBO 47.5% of the new entity. In 2004, the company acquired healthcare product distributor Vernon-Carus and the Melbourne based company, Stelmara Medical.

In January 2005 it increased its stake in Global Science from 47.5% to 67% and in March that year acquired the Australian business of Quantum Scientific. In December 2005 it raised its shareholding in Global Science to 100%. Global Science also acquired 100% of Scientific Supplies Ltd - a NZ-based specialty supplier of chemicals to the scientific market.

In August 2007, it acquired pharmaceuticals distributor PRNZ for $86.3m in cash and shares. In July 2008 it acquired MedBio Scientific.

In April 2009, EBO entered into a new issuance and share buyback as part of its profit distribution plan. Under the Profit Distribution Plan shareholders can elect to have the company buy back shares issued to them under the Plan at the issue price of $4.691798 per share.

As a result of shareholder elections the company achieved an off-market buy back of 279,875 shares. Of the total number of bonus shares issued in respect of the 2009 interim profit distribution (of 10.5 cps), 74.1% of shares are being retained with 25.9% electing the buyback option.

The company has elected to cancel all of the 279,875 shares bought back. With the issue of 1,080,305 new shares and the cancellation of 279,875 shares bought back, the total number of shares on issue is now 48,980,799.

On 14 June 2013, shareholders elected to proceed with a pro-rata renounceable Entitlement Offer of 7 new ordinary shares for every 20 existing ordinary shares held on the Record Date. The transaction settlement is expected to take place on or about 5 July 2013.

In November 2015, the company acquired Red Seal, a leading New Zealand natural health product business, for NZ$80 million.

Performance

The following information was extracted from EBOS Group Limited's full year results, released on 27 August 2025:

EBOS delivers solid FY25 result in line with guidance

Results reflect strong execution supported by continued investment

27 August 2025 – EBOS Group Limited today reports its full year results to 30 June 2025 (FY25). The results highlight EBOS’ continued track record of solid organic growth, operational excellence and strategic execution.

EBOS’ operating results included Underlying revenue growth of 12.0%1 to $12.3 billion, GOR of $1.6 billion and Underlying EBITDA of $585 million, up 7.5% on FY241. The Group also generated strong Underlying free cash flow of $302 million, with a cash realisation of 109%2. The FY25 EBITDA result is in line with our guidance range of $575 million to $600 million.

EBOS Group CEO, Adam Hall said: “In FY25, we reinforced our leadership positions across the healthcare and animal care sectors. We remain a leading pharmaceutical wholesaler in Australia and New Zealand. Our TerryWhite Chemmart network is a leading health-services focussed community pharmacy network in Australia. We are Australia and New Zealand’s leading hospital medicines wholesaler and one of ANZ and Southeast Asia’s leading medical technology distributors. In animal care we operate ANZ’s largest dry dog food brand3 in pet specialty and ANZ’s leading vet wholesaler.”

The Healthcare segment delivered impressive results amongst a challenging industry backdrop, achieving growth through new customer wins in Pharmacy wholesale and Contract Logistics, driving double-digit revenue growth. The Group made meaningful acquisitions in Southeast Asia, building upon the strong organic performance of the Transmedic business. Collectively, the Underlying financial results demonstrate the segment’s resilience and leading positions.

Within Animal Care, the branded business continued its growth momentum supported by new product development launches. The Group completed two acquisitions, one that established a leading position in the New Zealand vet wholesale industry and another that expanded our Australian pet food manufacturing capacity and will enable further expansion into high growth, high value product categories.

EBOS has delivered against its near-term strategic priorities, delivering profitable growth with a strong focus on maintaining our EBITDA margins. The Group remains confident in the growth across both the Healthcare and Animal Care segments, and the portfolio is uniquely placed through its leading brands and positions to capture the benefit arising from these supportive long-term industry trends. The balance sheet remains well positioned and cash flow strength supports future growth.

Chair, Elizabeth Coutts said: “Despite a material adjustment to business volumes, EBOS continued to deliver a strong underlying performance1. The Board has maintained the dividend at the same level as FY24 and the increased payout ratio reflects the Board’s confidence in the Group’s growth outlook and overall financial capacity.”